Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
181.4 SEK | +4.49% | +12.67% | +20.85% |
Apr. 29 | Nordic Shares Rose Monday; Ratos Series A Climbed Highest | DJ |
Apr. 26 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 56% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company sustains low margins.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 1026.77 and 438.87 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.85% | 2.51B | B+ | ||
+13.70% | 81.4B | C+ | ||
-29.20% | 70.18B | B- | ||
+9.72% | 29.08B | C+ | ||
-11.43% | 16.97B | B | ||
-0.43% | 16.96B | A- | ||
-0.31% | 15.26B | A- | ||
+3.42% | 12.41B | A- | ||
+28.34% | 11.79B | B- | ||
-30.70% | 11.95B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB